Partnership website: https://adr-association.eu/
The AI, Data and Robotics (ADR) partnership brings together industry, academia and the European Commission to
pursue innovative solutions on a large scale, pooling efforts, resources and investments to generate long-term positive impact, boost European competitiveness and technological sovereignty, as well as create jobs and growth.
The general objectives of the co-programmed European Partnership are:
The partnership will boost Europe’s competitiveness, societal well-being and environmental leadership, as leading
the world in researching, developing and deploying value-driven trustworthy AI, data and robotics based on European
fundamental rights, principles and values.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.